Pomalidomide Demonstrated Significant Progression-Free Survival and Overall Survival Advantages in Phase III Study of Heavily Pre-Treated Myeloma Patients

Pomalidomide Demonstrated Significant Progression-Free Survival and Overall Survival Advantages in Phase III Study of Heavily Pre-Treated Myeloma Patients

BOUDRY, Switzerland--(BUSINESS WIRE)--Oct. 23, 2012-- Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III, multi-center, randomized, open-label study (MM-003) of pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma was reviewed by a data safety monitoring board (DSMB). The DSMB determined MM-003 met the primary endpoint of improvement in progression-free survival (PFS) at the PFS final analysis. Additionally, at the OS interim analysis, the study crossed the superiority boundary for overall survival (OS), a key secondary endpoint that the study was also powered to evaluate. Improvements in PFS and OS were both highly statistically significant and clinically meaningful. As a result, the DSMB recommended that patients who had not yet progressed in the high-dose dexamethasone arm should be crossed-over to the pomalidomide plus low-dose dexamethasone arm.

Safety results observed in MM-003 were consistent with previous studies of pomalidomide in relapsed/refractory multiple myeloma patients. Full data from the study are being prepared for submission to a future medical meeting for presentation.

"The survival results in this study build on earlier observations of high response rates for pomalidomide and dexamethasone in multiple myeloma patients who had been exposed to multiple therapies, including immunomodulatory agents and proteasome inhibitors," said Dr. Jesus San Miguel, Head of the Department of Hematology at the University of Salamanca, Director of the Biomedical Research Institute of Salamanca and principal investigator in the study. "The continued progress of new agents in this area of disease, particularly in later-stage patients is critical as we look to extend remissions and survival for these individuals."

The MM-003 study compared pomalidomide plus low-dose dexamethasone to high-dose dexamethasone in patients who were relapsed on or refractory to at least two prior therapies that must have included both lenalidomide and bortezomib.

Patients in the pomalidomide arm received 4 mg of oral pomalidomide on days 1-21 of each 28-day cycle, with patients 75 years or younger also receiving 40 mg of oral low-dose dexamethasone and patients older than 75 years receiving 20 mg oral low-dose dexamethasone on days 1, 8, 15 and 22 of each 28-day cycle, until disease progression.

Patients in the comparator arm 75 years and younger received 40 mg oral high-dose dexamethasone on days 1-4, 9-12 and 17-20 of each 28-day cycle, and patients older than 75 years received 20 mg oral high-dose dexamethasone on days 1-4, 9-12 and 17-20 of a 28-day cycle, until disease progression.

The primary endpoint of the study was PFS, with the key secondary endpoint being OS (with alpha control), and other secondary endpoints including safety, response rates and time to progression.

A Marketing Authorisation Application (MAA) for pomalidomide in combination with dexamethasone was submitted to the EMA in May 2012 and Celgene anticipates a decision by European regulatory authorities in the second half of 2013.

Additionally, a new drug application (NDA) has been accepted for review by the U.S. Food and Drug Administration, with a Prescription Drug User Fee Act (PDUFA) date of Feb. 10, 2013.

These results are from an investigational study. Pomalidomide is not approved for the treatment of any indication.

About Pomalidomide

Pomalidomide is an IMiDs® compound. Pomalidomide and other IMiDs compounds continue to be evaluated in over 100 clinical trials. The IMiDs compound pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions.

About Multiple Myeloma

Multiple myeloma (also known as myeloma or plasma cell myeloma) is a cancer of the blood in which malignant plasma cells are overproduced in the bone marrow. Plasma cells are white blood cells that help produce antibodies called immunoglobulins that fight infection and disease. However, most patients with multiple myeloma have cells that produce a form of immunoglobulin called paraprotein (or M protein) that does not benefit the body. In addition, the malignant plasma cells replace normal plasma cells and other white blood cells important to the immune system. Multiple myeloma cells can also attach to other tissues of the body, such as bone, and produce tumors. The cause of the disease remains unknown.

About Celgene International Sàrl

Celgene International Sàrl, located in Boudry, in the Canton of Neuchâtel, Switzerland, is a wholly owned subsidiary and international headquarters of Celgene Corporation. Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

Source: Celgene International Sàrl

Celgene International Sàrl
Investors:
+41 32 729 8303
[email protected]
or
Media:
+41 32 729 8304
[email protected]